Pasithea Therapeutics
KTTA
8 hedge funds and large institutions have $985K invested in Pasithea Therapeutics in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
14% more funds holding
Funds holding: 7 → 8 (+1)
0.03% more ownership
Funds ownership: 0.14% → 0.17% (+0.03%)
9% less capital invested
Capital invested by funds: $1.09M → $985K (-$101K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$92.2K |
| 2 |
MSFP
Mark Sheptoff Financial Planning
Glastonbury,
Connecticut
|
+$60.7K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$55.5K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$23.9K |
| 5 |
BlackRock
New York
|
+$1.84K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$52K |
| 2 |
HF
HRT Financial
New York
|
-$22K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
KPF
1
K2 Principal Fund
Toronto,
Ontario, Canada
| $715K | – | – | – |
|
|
2
Citadel Advisors
Miami,
Florida
| $95K | +$92.2K | +3,647 | New |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $74K | +$55.5K | +2,194 | +346% |
|
|
MSFP
4
Mark Sheptoff Financial Planning
Glastonbury,
Connecticut
| $62K | +$60.7K | +2,400 | New |
|
|
TSS
5
Two Sigma Securities
New York
| $25K | +$23.9K | +945 | New |
|
|
6
BlackRock
New York
| $13K | +$1.84K | +73 | +17% |
|
7
JP Morgan Chase
New York
| $1K | – | – | – |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| – | -$52K | -1,469 | Closed |
|
|
HF
9
HRT Financial
New York
| – | -$22K | -637 | Closed |
|
10
Wells Fargo
San Francisco,
California
| – | +$51 | +2 | +100% |
|
KTTA Hedge Fund Activity: Q1 2022 in Review
8 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics (KTTA) for Q1 2022, worth a combined $985K — down 9.3% from $1.09M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new KTTA positions and 2 closed out — a net gain of 1 holder — while 3 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $92.2K. The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $52K sold.
- 8 institutional investors held Pasithea Therapeutics (KTTA) as of Q1 2022, up from 7 in Q4 2021.
- Funds reported $985K of Pasithea Therapeutics stock for Q1 2022, down 9.3% quarter-over-quarter.
- 3 funds opened new Pasithea Therapeutics positions in Q1 2022 and 2 closed out, a net change of +1 holder.
- The largest Pasithea Therapeutics buyer in Q1 2022 was Citadel Advisors, an estimated $92.2K added.
- The largest Pasithea Therapeutics seller in Q1 2022 was Tower Research Capital (TRC), an estimated $52K sold.
Based on aggregated 13F filings for Q1 2022.